01/15/2015 - 3:44pm

Mylan on Thursday announced the launch of lamivudine tablets, 100 mg, the generic version of Epivir-HBV from GlaxoSmithKline. 

01/12/2015 - 12:49pm

Perrigo Co. on Monday announced the launch of testosterone gel 1%, the therapeutic equivalent to Androgel 1% from AbbVie. 

01/09/2015 - 2:12pm

Camber Pharmaceuticals on Friday announced the launch of zolmitriptan tablets in 2.5- and 5-mg dosage strengths.

01/09/2015 - 2:06pm

Teva Pharmaceuticals on Friday announced the launch of linezolid injection, the generic equvialent to Zyvox injection from C.P. Pharmaceuticals.

01/08/2015 - 2:31pm

Camber Pharmaceuticals on Thursday announced the launch of valsartan tablets USP in 40-, 80-, 106- and 320-mg dosage strengths.

 

01/07/2015 - 11:18am

Teva Pharmaceutical on Tuesday announced the Food and Drug Administration approved the launch of the company's valsartan tablets, the generic version of Diovan tablets from Novartis. 

 

12/29/2014 - 12:26pm

Genentech last week announced that the Food and Drug Administration approved a supplemental biologics license application for Gazyva to be used in combination with chlorambucil chemotherapy in people with previously untreated chronic lymphocytic leukemia.

12/29/2014 - 11:29am

Novo Nordisk last week announced that the Food and Drug Administration approved the company's new drug application for Saxenda, a once-daily glucagon-like peptide-1 receptor agonist used as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adults.

12/29/2014 - 11:07am

Actavis and Adamas Pharmaceuticals last week announced that the Food and Drug Administration approved Namzaric. According to the companies, the drug is used to treat moderate to severe dementia of the Alzheimer's type in patients stablized on memantine hydrochloride and donepezil hydrochloride.